45.43
3.13 (7.40%)
| Penutupan Terdahulu | 42.30 |
| Buka | 43.03 |
| Jumlah Dagangan | 1,694,715 |
| Purata Dagangan (3B) | 1,143,066 |
| Modal Pasaran | 5,219,139,072 |
| Harga / Jualan (P/S) | 13.14 |
| Harga / Buku (P/B) | 20.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 May 2026 |
| EPS Cair (TTM) | -2.55 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 20.22% |
| Nisbah Semasa (MRQ) | 10.25 |
| Aliran Tunai Operasi (OCF TTM) | -229.84 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -134.32 M |
| Pulangan Atas Aset (ROA TTM) | -50.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -106.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Scholar Rock Holding Corporatio | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -2.0 |
| Purata | -0.63 |
|
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.35% |
| % Dimiliki oleh Institusi | 118.63% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Samsara Biocapital, Llc | 31 Dec 2025 | 6,897,652 |
| Redmile Group, Llc | 31 Dec 2025 | 5,220,846 |
| Bellevue Group Ag | 31 Dec 2025 | 4,056,592 |
| Eventide Asset Management, Llc | 31 Dec 2025 | 2,431,333 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 70.00 (BMO Capital, 54.08%) | Beli |
| Median | 58.00 (27.67%) | |
| Rendah | 53.00 (Barclays, 16.66%) | Beli |
| Purata | 58.86 (29.56%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 46.53 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BMO Capital | 04 Mar 2026 | 70.00 (54.08%) | Beli | 47.43 |
| Barclays | 04 Mar 2026 | 53.00 (16.66%) | Beli | 47.43 |
| Citigroup | 04 Mar 2026 | 58.00 (27.67%) | Beli | 47.43 |
| 09 Jan 2026 | 55.00 (21.07%) | Beli | 42.18 | |
| Piper Sandler | 04 Mar 2026 | 58.00 (27.67%) | Beli | 47.43 |
| Truist Securities | 04 Mar 2026 | 55.00 (21.07%) | Beli | 47.43 |
| HC Wainwright & Co. | 03 Mar 2026 | 58.00 (27.67%) | Beli | 44.31 |
| 26 Jan 2026 | 58.00 (27.67%) | Beli | 44.89 | |
| UBS | 07 Jan 2026 | 60.00 (32.07%) | Beli | 44.23 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Jan 2026 | Pengumuman | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Pengumuman | Scholar Rock Highlights 2026 Strategic Priorities |
| 05 Jan 2026 | Pengumuman | Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |